An interim analysis of Biolinerx Ltd.'s phase III test of motixafortide for stem cell mobilization in multiple myeloma patients has paved what CEO Philip Serlin called the "most efficient path to registration" for the candidate, an antagonist of the chemokine receptor CXCR4. Read More
Despite bad news from a phase I/II dose-escalation trial in relapsed/refractory metastatic pancreatic cancer, Bellicum Pharmaceuticals Inc. is staying in the game, albeit with far fewer employees. Read More
Ocular Therapeutix Inc. and Affamed Therapeutics Ltd. entered a license and collaboration agreement to develop and commercialize Dextenza and OTX-TIC in greater China, South Korea and the Association of Southeast Asian Nations markets. Read More
PERTH, Australia – Clinuvel Pharmaceuticals Ltd. announced two new pharmaceutical indications for its lead product, Scenesse (afamelanotide). “The company has until now focused on one drug and has slowly gathered evidence and is now in a position to add other products to its pipeline,” Clinuvel CEO Philippe Wolgen told BioWorld. Read More
HONG KONG – Cstone Pharmaceuticals Co. Ltd. inked a licensing agreement with Legochem Biosciences Inc. for LCB-71, the latter’s antibody-drug conjugate. Read More
Gracell Biotechnologies Inc. has closed a $100 million series C financing round to advance its CAR T-cell therapy candidates, including autologous product candidate, GC-012F, and allogeneic product candidate, GC-027. Both candidates are in investigator-initiated phase I trials in China. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aligos, Axovant, Bellicum, Biolinerx, Cerevel, Lilly. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: ADC Therapeutics, Genmab, Genprex, Havn, Innovation Pharmaceuticals, Janssen, Novartis, Oscine, OSE Immunotherapeutics, Protagonist, Sana. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Algernon, Avrobio, Biocryst, Biogen, Cerecin, Equillium, Nexus, Novartis, Novo Nordisk, Regeneron, União Química, Trevena. Read More
